Teikoku Pharma develops life-changing therapies through advanced science and technical ingenuity.
Teikoku Pharma USA announces positive topline results from Phase 2 clinical trial of TPU-006, non-opioid pain management patch in Abdominoplasty Surgery.
Teikoku Pharma granted FDA Fast Track Designation for TPU-006, a Novel 4-day Dexmedetomidine Transdermal System for Post Operative Pain Management
Teikoku Pharma USA Announces Positive Topline Results from Phase 2 Clinical Trial of TPU-006, Non Opioid Pain Management Patch in Bunionectomy Surgery
Teikoku Pharma USA and Luoxin Pharmaceutical Enter into License Agreement for Docetaxel, Non-Alcohol Formula
Teikoku Pharma USA is a global specialty pharmaceutical company with a focus on developing first and best-in-class therapeutic products in the areas of pain management, CNS disorders, and Dermatology. Our Lidoderm product has helped millions of patients in 59 countries.
We explore a variety of opportunities to develop drugs that improve patient lives and take an opportunistic approach to our programs, both independently and collaboratively with like-minded partners.
TPU-006 is an investigational non-opioid analgesic designed to deliver dexmedetomidine for four days or longer post-surgery.
With deep expertise in dosage form development plus comprehensive manufacturing capabilities, we create both the formulations and the delivery mechanisms that bring innovative ideas to life.